Health
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"image","alt":"Indivior Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Indivior Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/a420cc32e120a253fc3fcae6c1c87744"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rz15af5LMzN0LAfh3VV3ag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a420cc32e120a253fc3fcae6c1c87744","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":270,"olType":false},{"type":"text","content":"RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder (OUD). These outcomes were more favorable compared to both patients adherent to other medications for OUD (MOUD) and to those who were nonadherent to MOUD.","length":609,"tagName":"p"},{"type":"text","content":"These findings add to growing evidence that long-acting injectable buprenorphine treatment supports sustained engagement in care and reduces costly acute healthcare use.","length":169,"tagName":"p"},{"type":"text","content":"To evaluate the relationship between treatment adherence, medication type, healthcare utilization, and costs, patients were grouped based on adherence level and primary MOUD received during follow-up including: those adherent to SUBLOCADE, those not adherent to SUBLOCADE but adherent to other MOUD (e.g., transmucosal buprenorphine), and those who were not adherent to any MOUD.","length":379,"tagName":"p"},{"type":"text","content":"Patien...